Xencor (STU:XE9) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:XE9 Xencor Inc STU:XE9
49 GF Score
Price €17.10
GF Value €8.04
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Xencor Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:XE9 vs MGTX, WVE, CGEM: Short Interest Comparison

For the Biotechnology subindustry, Xencor's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xencor Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xencor's Short Interest distribution charts can be found below:

* The bar in red indicates where Xencor's Short Interest falls into.


STU:XE9
49GF Score
Xencor Inc STU:XE9
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xencor (STU:XE9) Overvalued in 2026?

Based on GuruFocus' analysis, Xencor stock appears to be overvalued. The current stock price of €17.10 is trading 112.7% above its estimated GF Value™ of €8.04. GuruFocus considers Xencor to be Significantly Overvalued.

Key valuation signals for STU:XE9:

  • Short Interest:
  • GF Value™: €8.04 vs. price of €17.10 (112.7% above fair value)
  • GF Score™: 49/100 with 8 warning signs

No single metric tells the full story. See the STU:XE9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xencor Business Description

Other Exchanges XNCR:USA
Address 465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
49GF Score

Get the complete analysis for STU:XE9

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.10
Price
€8.04
GF Value